Groundbreaking trial aims to protect moms and babies from mpox
NCT ID NCT06844500
Summary
This study is testing the safety and immune response of the MVA-BN mpox vaccine in pregnant and recently delivered women in the Democratic Republic of the Congo, where mpox is a risk. It will enroll 359 women to receive two vaccine doses either during pregnancy or right after giving birth. The main goal is to see if the vaccine is safe for both mothers and their babies and if it provides protective antibodies that can be passed to the infant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boende Hôpital Général de Référence
Boende, Province de La Tshuapa, Democratic Republic of the Congo
Conditions
Explore the condition pages connected to this study.